Immunic's Upcoming Participation in Key Investor Conferences This November

Immunic's Upcoming Participation in Key Industry and Investor Conferences This November

Immunic, Inc. (Nasdaq: IMUX), a prominent biotechnology entity, is set to take part in several key industry and investor conferences this November, showcasing its forward-thinking approach in developing orally administered therapies. This participation reflects its commitment to chronic inflammatory and autoimmune diseases, highlighting the company's advancements and initiatives.

Overview of Events

From November 3rd to 5th, Immunic’s CEO Daniel Vitt, Ph.D., Chief Scientific Officer Hella Kohlhof, Ph.D., and Vice President of Investor Relations and Communications Jessica Breu will be in Vienna, Austria, for the BIO-Europe conference. During this three-day event, they will engage in significant partnering activities. Stakeholders and interested parties can schedule meetings via the BIO-Europe partneringONE portal or directly by reaching out to Jessica Breu ([email protected]).

Shortly after, on November 19th and 20th, Dr. Vitt, alongside President and COO Jason Tardio, will host one-on-one meetings in London at the Jefferies Global Healthcare Conference. To arrange a meeting in this environment focused on healthcare innovation, interested individuals can also contact Jessica Breu for assistance.

About Immunic, Inc.

Immunic, Inc. specializes in crafting a robust pipeline of therapies aimed at treating chronic inflammatory and autoimmune diseases. The firm’s flagship developmental program includes vidofludimus calcium (IMU-838), which is currently undergoing Phase 3 clinical trials targeting relapsing multiple sclerosis, with top-line data anticipated by the end of 2026. Notably, this therapy showcased efficacy in Phase 2 trials for patients experiencing both relapsing-remitting and progressive multiple sclerosis.

The mechanism of vidofludimus calcium is remarkably innovative, as it functions as a first-in-class Nurr1 activator while also inhibiting dihydroorotate dehydrogenase (DHODH) — a mechanism that supports its neuroprotective and anti-inflammatory capabilities.

In addition to IMU-838, Immunic is progressing in the development of IMU-856, which aims to enhance gut barrier integrity and facilitate bowel epithelium regeneration, valuable in treating gastrointestinal ailments like celiac disease, inflammatory bowel disease, and others. A further promising candidate, IMU-381, is in preclinical testing focused on gastrointestinal conditions.

Conclusion

The upcoming conferences represent a pivotal platform for Immunic to elucidate its ongoing projects and engage with industry peers and investors. By presenting its innovative therapies, Immunic is gearing up to make substantial strides within the biotechnology domain, further aiding patients suffering from chronic inflammatory and autoimmune diseases. With sustained commitment and scientific inquiry, Immunic continues to navigate the complex landscape of biopharmaceutical development.

For further knowledge on Immunic’s innovative work and future updates, please visit Immunic’s official site.

Contact Information

For inquiries regarding meetings and conference participation, Jessica Breu, VP of Investor Relations and Communications, is available at +49 89 2080 477 09 or via her email at [email protected].

For further inquiries about their developments, please reach out to their US IR Contact, Paula Schwartz from Rx Communications Group at +1 917 633 7790 or via email, [email protected].